Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9197
Title: Antifibrotic and anthelminthic effect of casticin on Schistosoma mansoni-infected BALB/c mice
Authors: Pekkle Lam, Ho Yin
Liang, Ting-Ruei
Lan, Yi-Chia
Chang, Kai-Chih
Cheng, Po-Ching
Peng, Shih-Yi
Keywords: Casticin;
Fibrosis;
Schistosoma mansoni;
Schistosomiasis
Issue Date: 1-Apr-2022
Publisher: Elsevier Taiwan LLC
Abstract: Abstract Background/Purpose: Schistosomiasis is an important tropical disease caused by Schistosoma. Although the pathogenesis of liver fibrosis has been intensively studied, the choice of effective treatment is still inadequate. In this study, we aimed to investigate the potential of using Casticin to treat Schistosoma mansoni-induced liver fibrosis. Methods: BALB/c mice were divided into three groups e control, infection, and treatment group. The infection and treatment group were percutaneously infected with 100e120 cercariae. Mice from the treatment group were treated with 20 mg/kg/day Casticin for 14 consecutive days to investigate the potential protective effects of Casticin. Mice were sacrificed and were used for histological, RNA, protein, and parasite burden analysis. Results: Our results showed that hepatic fibrosis was significantly attenuated, as indicated by histology and reduction of fibrotic markers such as collagen AI, transforming growth factor b (TGF-b), and a-smooth muscle actin (a-SMA). Furthermore, Casticin treatment significantly reduced worm burden. Anthelmintic effect of Casticin was also observed by scanning electron microscopyConclusion: Collectively, our study suggested that Casticin may be a beneficial candidate in treating S. mansoni infection
URI: http://localhost:8080/xmlui/handle/123456789/9197
ISSN: 1684-1182
Appears in Collections:VOL 55 NO 2 2022

Files in This Item:
File Description SizeFormat 
314-322.pdf1.93 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.